Launch of Psychedelics DNA Test Kit Phase 1 clinical trial for DMT progressing as planned Pre-clinical In Vivo work scheduled to start at Israeli CRO Strengthened expertise focused on driving initiatives forward Upgraded OTC Listing Financial Update Vancouver, British Columbia–(Newsfile Corp. – May 14, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (OTCQB: ENTBF) (“Entheon” or the…

Source

Previous articlePTSF59 – Bipolar and Psychedelics, with Benjamin Mudge
Next articleMindMed Receives FDA Type C Meeting Response for Project Lucy Phase 2b Clinical Trial